- Home
- CM vs BMY Comparison
CM vs BMY Comparison
Compare CM & BMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CM | BMY |
|---|---|---|
| Founded | 1867 | 1887 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 81.0B | 95.0B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | CM | BMY |
|---|---|---|
| Price | $90.87 | $51.56 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 12 |
| Target Price | ★ $107.50 | $55.58 |
| AVG Volume (30 Days) | 924.3K | ★ 15.1M |
| Earning Date | 12-04-2025 | 10-30-2025 |
| Dividend Yield | 3.06% | ★ 4.80% |
| EPS Growth | ★ 17.72 | N/A |
| EPS | ★ 6.12 | 2.97 |
| Revenue | $19,117,584,096.00 | ★ $48,034,000,000.00 |
| Revenue This Year | $14.31 | $0.23 |
| Revenue Next Year | $3.73 | N/A |
| P/E Ratio | ★ $14.75 | $17.39 |
| Revenue Growth | ★ 13.50 | 1.26 |
| 52 Week Low | $53.62 | $42.52 |
| 52 Week High | $91.57 | $63.33 |
Technical Indicators
Market Signals| Indicator | CM | BMY |
|---|---|---|
| Relative Strength Index (RSI) | 69.75 | 65.17 |
| Support Level | $90.21 | $48.22 |
| Resistance Level | $91.57 | $52.51 |
| Average True Range (ATR) | 1.39 | 1.10 |
| MACD | 0.49 | 0.31 |
| Stochastic Oscillator | 91.28 | 81.50 |
Price Performance
Historical ComparisonAbout CM Canadian Imperial Bank of Commerce
Canadian Imperial Bank of Commerce is Canada's fifth-largest bank with around CAD 1 trillion in assets. It operates four business segments: Canadian retail and business banking, Canadian commercial banking and wealth management, US commercial banking and wealth management, and capital markets. It serves approximately 14 million personal banking and business customers, primarily in Canada and the US.
About BMY Bristol-Myers Squibb Company
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.